8.5 Diuretics and Decongestion Strategies

Why Decongestion Is the Whole Admission

Test-plan item III.C.3 is diuretics, and on the CMC exam diuretic questions are really decongestion questions. Most heart failure admissions are driven by congestion rather than low output, and residual congestion at discharge is the single strongest predictor of 30-day readmission and death. The nurse controls almost every variable that determines whether decongestion succeeds: whether the dose was actually adequate, whether the response was measured early enough to act on, and whether electrolytes were replaced before they stopped the diuresis.

Loop Diuretic Pharmacology

Loop diuretics inhibit the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, blocking reabsorption of roughly 25% of filtered sodium. They circulate about 95% bound to albumin, are filtered poorly, and must be actively secreted into the tubular lumen by organic anion transporters. This has three consequences that explain most bedside failures: the drug must reach the lumen to work, competing anions block secretion, and the response is threshold-dependent - below a certain luminal concentration nothing happens, and above the ceiling a larger single dose adds nothing.

Ceiling dose is the single IV dose above which no additional natriuresis occurs: roughly 40 mg of furosemide equivalent in normal renal function, 80-160 mg in heart failure, and up to 160-200 mg with an eGFR below 30 mL/min/1.73 m2. Once you are at ceiling, increase the frequency, not the size, of the dose - twice or three times daily, or convert to an infusion.

Dosing the naive versus the chronically treated patient. A diuretic-naive patient starts at furosemide 20-40 mg IV. A patient already on a home oral loop diuretic must receive an IV dose equal to 2 to 2.5 times the total home oral dose, given as at least twice-daily dosing - the strategy tested in the DOSE trial, where the high-dose arm produced greater dyspnea relief, greater weight and net fluid loss, and more transient creatinine rise that did not translate into worse outcomes. The same trial found no meaningful difference between intermittent bolus and continuous infusion for the primary endpoints, so an infusion is not automatically superior. Reserve continuous infusion (furosemide 5-20 mg/h or bumetanide 0.5-2 mg/h after a loading bolus) for severe diuretic resistance or right-sided failure where maintaining a steady luminal concentration above threshold matters most.

Administration rate is a safety item. Push furosemide no faster than 4 mg/min - a 20-40 mg dose over 1-2 minutes, with doses above about 120 mg given as an infusion rather than a push. Bumetanide is limited to 1 mg/min. Exceeding these rates, particularly with concurrent aminoglycosides or renal failure, causes tinnitus and usually reversible sensorineural hearing loss.

Sequential Nephron Blockade and the Adjunct Agents

When the loop diuretic alone is insufficient, the strategy is to block sodium reabsorption at a second nephron site rather than to keep escalating a single agent past its ceiling.

Thiazides and thiazide-like agents block the sodium-chloride cotransporter in the distal convoluted tubule, the exact segment that hypertrophies during chronic loop therapy. Metolazone 2.5-10 mg orally is the classic addition; chlorothiazide 500-1,000 mg IV is used when absorption is unreliable. The timing rule is examinable: give the thiazide 30-60 minutes before the loop dose so that distal blockade is already established when the sodium load arrives. Sequential blockade is powerful and dangerous - expect brisk diuresis, profound hypokalemia and hypomagnesemia, hyponatremia, and volume depletion, and check electrolytes at least daily, often twice daily.

Mineralocorticoid receptor antagonists block aldosterone-driven sodium reabsorption in the collecting duct. Distinguish the two dosing intents. Spironolactone 25-50 mg or eplerenone 25-50 mg daily is the mortality dose in heart failure with reduced ejection fraction. Higher natriuretic doses of 50-100 mg have been used for decongestion, but a randomized trial of high-dose spironolactone in acute heart failure did not improve congestion endpoints, so they are an adjunct rather than a mainstay. Spironolactone causes gynecomastia and breast tenderness in roughly 10% at higher doses; eplerenone is more selective and does not. Both cause hyperkalemia - avoid initiation with a potassium above 5.0 mEq/L or an eGFR below 30 mL/min/1.73 m2.

Acetazolamide inhibits carbonic anhydrase in the proximal tubule, reducing proximal sodium and bicarbonate reabsorption so that more sodium is delivered downstream to the loop. The ADVOR trial added acetazolamide 500 mg IV once daily to standardized IV loop therapy and increased successful decongestion at day 3 from 30.5% to 42.2%, with a shorter length of stay. Acetazolamide has a second, elegant use: because it causes bicarbonate wasting, it simultaneously corrects the hypochloremic contraction alkalosis that chronic loop therapy produces. That alkalosis is not cosmetic - it blunts respiratory drive, aggravates hypokalemia, potentiates digoxin toxicity, and independently impairs further diuresis. Hypochloremia is now recognized as a marker of diuretic resistance and poor prognosis in its own right.

SGLT2 inhibitors (dapagliflozin or empagliflozin 10 mg daily) produce natriuresis and osmotic diuresis. Their decongestive contribution during a single admission is modest; the reason to start one before discharge is the outcome benefit, and the practical bonus is that they often permit a lower maintenance loop dose.

Tolvaptan is an oral vasopressin V2 receptor antagonist producing pure aquaresis - free water excretion without sodium loss. Dose 15-30 mg daily, reserved for hypervolemic hyponatremia (sodium below about 130 mEq/L) with persistent congestion. It improves symptoms and weight but not mortality. Do not fluid-restrict during initiation, limit therapy to 30 days, avoid it in liver disease, and do not allow the sodium to rise more than 8-12 mEq/L in 24 hours because of osmotic demyelination risk.

Diuretic Resistance: Mechanisms and the Stepwise Response

Diuretic resistance is failure to decongest despite an appropriate dose. Work through the mechanisms:

1. Braking phenomenon - post-diuretic sodium retention once the drug level falls below threshold, which is why once-daily dosing plus a liberal sodium diet nets zero.
2. Distal tubular hypertrophy - chronic loop exposure hypertrophies the distal convoluted tubule, which reclaims the sodium the loop delivered.
3. Impaired delivery to the tubule - low cardiac output, high central venous pressure and renal venous congestion, and low GFR all reduce the amount of drug secreted into the lumen.
4. Hypoalbuminemia and competing anions - less albumin-bound drug reaching the transporter; uremic anions, NSAIDs, and probenecid compete for secretion.
5. NSAIDs - blunt prostaglandin-mediated afferent vasodilation and directly antagonize the natriuretic response.
6. Excessive sodium intake and ongoing neurohormonal activation.

The stepwise response: double the IV loop dose to ceiling, then increase frequency or convert to infusion, then add sequential blockade (acetazolamide if alkalotic, thiazide or metolazone if chronically loop-treated), then fix perfusion with an inotrope or vasodilator if the profile is cold and wet, then remove NSAIDs and restrict sodium, and finally escalate to ultrafiltration or renal replacement therapy when the kidney will not respond - covered in its own section.

Measuring Whether Decongestion Is Actually Working

The most common CMC scenario is a patient who has received a large diuretic dose and is still congested six hours later. The exam wants you to have measured the response early enough to act.

The spot urine sodium is the highest-yield item on this table because it converts a six-hour wait into a two-hour decision. A value below 50-70 mEq/L two hours after a dose reliably predicts a poor natriuretic response, and natriuresis-guided titration increases both natriuresis and diuresis compared with usual care. One liter of fluid equals approximately 1 kg of weight, and daily weights are more reliable than recorded intake and output, which are notoriously incomplete.

Do not stop at "the patient diuresed." Assess residual congestion before discharge: jugular venous distention, orthopnea, hepatojugular reflux, persistent edema, and failure of natriuretic peptide to fall by roughly 30%. A patient discharged still congested is a patient who returns.

Electrolyte and Metabolic Consequences

The Nursing Monitoring Plan

Build the plan around decision points, not routine. Weigh at a fixed time on a fixed scale. Send a spot urine sodium 1-2 hours after the first IV dose and after any dose change, and escalate on the result rather than waiting for the physician round. Track hourly urine output for the first 6 hours after each dose change. Draw a basic metabolic panel and a magnesium level daily, and twice daily when a thiazide has been added. Replace potassium and magnesium before they become the reason the diuresis stalls. Review the medication list for NSAIDs and high-sodium vehicles. Watch the blood pressure and mentation for over-diuresis at the same time you watch the neck veins for under-diuresis - the two errors have opposite fixes and identical-looking fatigue. Finally, teach the transition: the discharge oral dose is not the inpatient IV dose, torsemide or bumetanide may be the better oral agent in a patient with gut edema, and daily weights with a documented call threshold of a 2-3 pound overnight gain or a 5-pound gain in a week are what keep the patient out of the hospital.